Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Observational Data Analysis in EuroSIDA (0518-058)

This study has been completed.
EuroSIDA Coordinating Centre, Copenhagen HIV Programme (CHIP)
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: February 26, 2010
Last updated: February 2, 2015
Last verified: February 2015

The main objective of the study is to monitor health outcomes associated with antiretroviral drugs in a population of HIV-infected patients.

HIV-1 Infections

Study Type: Observational
Study Design: Observational Model: Cohort
Official Title: Observational Safety Data Analysis From Routine Follow-up in the EuroSIDA Study of Patients Treated With Raltegravir in a Five-Year Post Authorization Period

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Incidence of Malignancy (All malignancy collected) [ Time Frame: January 2000 - December 2014 ] [ Designated as safety issue: Yes ]
  • Incidence of clinically important liver outcomes (as measured by hepatic encephalopathy (stage III or IV) or discontinuation of Raltegravir use where liver toxicity is listed as the reason for discontinuation. [ Time Frame: January 2000 -December 2014 ] [ Designated as safety issue: Yes ]
  • Incidence of Lipodystrophy events as measured by the detection of the first reported event for loss of fat from extremities, buttocks or face. [ Time Frame: January 2000 - December 2014 ] [ Designated as safety issue: Yes ]
  • All cause mortality (as measured by report of any death as collected for the follow-up visit for each patient) [ Time Frame: January 2000 - December 2014 ] [ Designated as safety issue: Yes ]

Enrollment: 7742
Study Start Date: May 2008
Study Completion Date: January 2015
Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
HIV-infected patients from the EuroSIDA study who are exposed to Raltegravir
Historical comparison cohort of HIV-infected patients from the EuroSIDA study from the time period prior to the availability of Raltegravir for patient use
Concurrent comparison cohort of HIV-infected patients from patients in the EuroSIDA study that are contemporaneous with Raltegravir users but who are not exposed to Raltegravir

Detailed Description:

Time Perspective: Retrospective and Prospective


Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Adults 16 years old and older in the EuroSIDA database


Inclusion Criteria:

  • Adults 16 years old and older with HIV-1

Exclusion Criteria:

  • Subjects will be excluded if they have no prospective follow up
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01078233

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
EuroSIDA Coordinating Centre, Copenhagen HIV Programme (CHIP)
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT01078233     History of Changes
Other Study ID Numbers: 0518-058, 2010_020, EP08025.005
Study First Received: February 26, 2010
Last Updated: February 2, 2015
Health Authority: Denmark: Danish Medicines Agency

Keywords provided by Merck Sharp & Dohme Corp.:
antiretroviral treatment
HIV Cohort
Treatment processed this record on March 03, 2015